Search
RD06-04
go.drugbank.com/drugs/DB24647InvestigationalRD06-04 is under investigation in clinical trial NCT06986018 (Clinical Study on the Targeted CD19 Universal CAR-T Cell Injection (RD06-04) for the Treatment of IIM and AAV).
J147
go.drugbank.com/drugs/DB13957ExperimentalJ147 is an experimental drug with reported effects against both Alzheimer's disease and ageing in mouse models of accelerated aging. … derivative and a potent neurogenic and neuroprotective drug candidate initially developed for the treatment of neurodegenerative conditions associated with aging that impacts many pathways implicated in
Synonyms: N-(2,4-Dimethylphenyl)-2,2,2-trifluoro-N'-[(E)-(3-methoxyphenyl)methylene]acetohydrazideDexloxiglumide
go.drugbank.com/drugs/DB04856InvestigationalAs the D-isomer of loxiglumide, it retains all pharmacological properties of loxiglumide but is more potent. … Dexloxiglumide is a selective cholecystokinin type A (CCKA) receptor antagonist in phase III testing by Rottapharm in Europe only, as U.S. trials have been discontinued.
MP4
go.drugbank.com/drugs/DB05313InvestigationalMP4 is a hemoglobin-based oxygen carrier designed to serve as an alternative for blood transfusions.
ATL-104
go.drugbank.com/drugs/DB05670InvestigationalIn animal models, ATL-104 aids regeneration of the gastrointestinal tract after treatment with chemotherapeutic agents.
Lysergic acid diethylamide
go.drugbank.com/drugs/DB04829IllicitInvestigationalExplanations in terms of LSD physically remaining in the body for months or years after consumption have been discounted by experimental evidence. … However, not all published case reports of chronic flashbacks appear to describe an anxious hyper-vigilant state reminiscent of post-traumatic stress disorder.
Synonyms: N,N-diethyl-D-lysergamide, D-lysergic acid diethylamideG305
go.drugbank.com/drugs/DB17292InvestigationalG305 is a [recombinant NY-ESO-1 protein] plus glucopyranosyl lipid A (GLA) in a stable emulsion (SE). G305 is an active component of CMB305 along with [LV305].[L47346]
LX201
go.drugbank.com/drugs/DB04943InvestigationalLX201 is implanted subconjunctivally (beneath the transparent membrane covering the white of the eye) in a minimally invasive procedure. … The implant is being developed clinically for the prevention of rejection in corneal transplantation. It is being developed by Lux Biosciences, Inc.
OSI-7836
go.drugbank.com/drugs/DB05837ExperimentalIt is also more active than ara-C (another clinically used nucleoside analog) in all nine models and more active than either paclitaxel or cisplatin in the two lung xenograft models tested.